Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 13, 2023

SELL
$16.14 - $24.94 $554,941 - $857,512
-34,383 Reduced 8.71%
360,151 $6.19 Million
Q4 2022

Jan 23, 2023

SELL
$18.07 - $25.6 $11,438 - $16,204
-633 Reduced 0.16%
394,534 $7.95 Billion
Q3 2022

Oct 26, 2022

SELL
$20.23 - $31.73 $36,110 - $56,638
-1,785 Reduced 0.45%
395,167 $8.56 Million
Q2 2022

Jul 25, 2022

SELL
$17.91 - $52.25 $235,140 - $685,990
-13,129 Reduced 3.2%
396,952 $11.2 Million
Q1 2022

May 02, 2022

SELL
$41.58 - $80.89 $362,203 - $704,632
-8,711 Reduced 2.08%
410,081 $18.9 Million
Q4 2021

Jan 28, 2022

BUY
$66.92 - $84.79 $28 Million - $35.5 Million
418,792 New
418,792 $35.2 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $171M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Allspring Global Investments Holdings, LLC Portfolio

Follow Allspring Global Investments Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.